ACS chemical neuroscience molecule spotlight on STX209 (Arbaclofen)

Research output: Contribution to journalReview article

2 Scopus citations

Abstract

STX209 (arbaclofen) is a γ-amino butyric acid type B (GABA B) receptor agonist from Seaside Therapeutics currently in clinical trials for autism spectrum disorders (ASD). The company has initiated a phase 2b study after positive results from a phase 2a trial, announced September 2010 (http://www.seasidetherapeutics.com/sites/default/files/STX209-ASD-P2b Trial-Initiation%206%2021%202011%20Final.pdf).

Original languageEnglish (US)
Number of pages1
JournalACS Chemical Neuroscience
Volume2
Issue number8
DOIs
StatePublished - Aug 17 2011

Keywords

  • GABA
  • STX209
  • autism spectrum disorder (ASD)

ASJC Scopus subject areas

  • Biochemistry
  • Physiology
  • Cognitive Neuroscience
  • Cell Biology

Fingerprint Dive into the research topics of 'ACS chemical neuroscience molecule spotlight on STX209 (Arbaclofen)'. Together they form a unique fingerprint.

  • Cite this